Skip to main content
Premium Trial:

Request an Annual Quote

A Banner Year?

Contradicting a report issued last week that found venture capital funding to the life sciences is sharply down for the second quarter, the blog Seqonomics says that investments into genomics may reach its highest level, by dollar amounts, ever in 2012.

Using data from the free database CrunchBase, Art Wuster, a postdoc at the Sanger Institute, calculates that, in 2012, more than $400 million in investments will be made into genomics firms. He says that while the number of investments into genomics firms for 2012 — 17 — are on track to be the lowest since 2008, the average size of the investments, an estimated $26.6 million, is the highest ever.

"For genomics startups this means that it may be harder to get funding, but that once you get it, it will be generous," Wuster says.

If Wuster is correct, his estimates would be in sharp contrast to what some VC funds tell Daily Scan's sister publication GenomeWeb Daily News — that the VC environment for the 'omics and molecular diagnostics space remains bleak, mirroring the broader life sciences space.

Joshua Phillips tells GWDN that in addition to fewer deals, VC firms may be limiting the size of their investments and putting them only into those companies that are "ultra capital efficient" to maximize their returns.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.